Chargement en cours...
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
BACKGROUND: Inhibitors targeting programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) have unprecedented effects in cancer treatment. However, the objective response rates (ORRs), progression-free survival (PFS), and overall survival (OS) of PD-1/PD-L1 blockade monotherapy have not b...
Enregistré dans:
| Publié dans: | Ther Adv Med Oncol |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7366397/ https://ncbi.nlm.nih.gov/pubmed/32728392 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920937612 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|